^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + TP53 mutation + RB1 mutation

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1, RB1, RB Transcriptional Corepressor 1, Protein Phosphatase 1 Regulatory Subunit 130, Prepro-Retinoblastoma-Associated Protein, Retinoblastoma-Associated Protein, Retinoblastoma 1, P110-RB1, P105-Rb, Pp110, PRb, Exon 17 Tumor GOS561 Substitution Mutation Causes Premature Stop, GOS563 Exon 17 Substitution Mutation Causes Premature Stop, Retinoblastoma Suspectibility Protein, Osteosarcoma, PPP1R130, OSRC, RB, Rb, pRb
    Entrez ID:
    1956; 7157; 5925
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    7ms
    Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features. (PubMed, Front Oncol)
    Spatiotemporal heterogeneity profiled by the multi-omics analysis method suggested that LU2D possibly had the same lineage as LU2B (similarity score, 12.9%; shared neoantigens, n = 71); gefitinib treatment and EGFR, TP53, and RB1 mutations suggested the possibility that LU2E might result from histology transformation of LU2C despite the lack of LU2C biopsy and its histology...This novel multi-omics analysis method improves the accuracy of lineage tracing by tracking the spatiotemporal heterogeneity of serial samples. Further validation is required for its clinical application in accurate diagnosis, disease management, and improving prognosis.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1)
    |
    TP53 mutation • EGFR mutation • RB1 mutation • EGFR mutation + TP53 mutation + RB1 mutation
    |
    gefitinib
    over1year
    Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer (IASLC-TTLC 2023)
    The inferior outcomes in patients with EGFR-mutant NSCLC with tumors harboring a co-occurring TP53 mutation may be due to additional TSG alterations rather than TP53 mutational status alone. This may have implications for understanding the biologic underpinnings of differential outcomes to EGFR-TKIs.
    Clinical • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1)
    |
    TP53 mutation • EGFR mutation • TP53 wild-type • EGFR mutation + TP53 mutation + ARID1A mutation • EGFR mutation + TP53 mutation + BRCA1 mutation • EGFR mutation + TP53 mutation + NF1 mutation • EGFR mutation + TP53 mutation + PTEN mutation • EGFR mutation + TP53 mutation + RB1 mutation